Physician profile
Mark Alan Posner
NPI 1508869637
$10,920.39
in general payments reported to CMS, 2019-2025
33 companies · $706 in 2025
The $706 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,471 · 2020: $1,167 · 2021: $1,263 · 2022: $1,615 · 2023: $1,413 · 2024: $2,286 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,310 · Education: $94.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,309.85 |
| Education | $94.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,264.06 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $1,246.76 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,098.37 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $864.69 | 2019-2025 | Dupixent |
| Csl Behring | $768.76 | 2019-2025 | Hizentra, Haegarda |
| Pfizer INC. | $658.21 | 2019-2024 | |
| Kaleo, INC. | $624.83 | 2019-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $595.48 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Genentech USA, INC. | $456.41 | 2019-2025 | Xolair |
| Alk-Abello, INC | $283.27 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $225.90 | 2021-2024 | Orladeyo |
| Blueprint Medicines Corporation | $218.20 | 2023-2025 | Ayvakit |
| Amgen INC. | $210.68 | 2021-2024 | Tezspire |
| Grifols USA, LLC | $171.87 | 2019-2025 | Xembify |
| Covis Pharma Gmbh | $135.29 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bio Products Laboratory USA, INC. | $131.93 | 2020-2023 | Coagadex, Gammaplex |
| Octapharma USA, INC. | $121.90 | 2019-2023 | Cutaquig |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.00 | 2019-2022 | |
| Optinose US, INC. | $115.33 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $114.86 | 2019-2022 | |
| Shire North American Group INC | $92.11 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $64.54 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $49.67 | 2019-2025 | |
| Abbvie INC. | $49.01 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $41.90 | 2025 | Neffy |
| Organon LLC | $41.49 | 2025 | Vtama |
| Horizon Therapeutics Plc | $30.66 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $27.58 | 2019-2023 | |
| Verona Pharma, INC. | $26.48 | 2025 | Ohtuvayre |
| Hikma Pharmaceuticals USA | $19.97 | 2023 | Ryaltris |
| Leo Pharma INC. | $19.17 | 2022 | |
| Eyevance Pharmaceuticals LLC | $16.85 | 2021 | |
| Aytu Biopharma, INC. | $13.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Posner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.